Gene-based therapy company fights HIV/AIDS with $15 million financing
TUCSON, Ariz. – Calimmune Inc., a clinical-stage gene therapy company, has successfully completed its $15 million Series B financing round, led by a large pharmaceutical company. Alexandria Venture Investments also joined with existing investors including RA Capital Healthcare Fund LP and Translational Accelerator LLC. Proceeds will be used to progress the company’s ongoing HIV/AIDS clinical…